I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 582593964 US, on the date shown below in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: May 23, 2007 Signature: _____ (Lori Sims)

Patent
Docket No. 577712000200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Stephen TOMLINSON et al.

Serial No.: 10/534,772

International Filing Date: November 13, 2003

International Appl. No.: PCT/US2003/036459

For: COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS

Examiner: Not Yet Assigned

Group Art Unit: 1653

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

☐ With the application; accordingly, no fee or separate requirements are required.

☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.

- ☐ A fee is required. A check in the amount of __ is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.

☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.

- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 577712000200.

Dated: May 23, 2007

Respectfully submitted,

By_____
Jian Xiao
Registration No.: 55,748
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-5736

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 8

Complete if Known	
Application Number	10/534,772
Filing Date	(Int'l.) November 13, 2003
First Named Inventor	Stephen TOMLINSON
Art Unit	1653
Examiner Name	Not Yet Assigned
Attorney Docket Number	577712000200

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-2005/0265995-A1	12-01-2005	Tomlinson et al.	
	2.	US-2006/0014681-A1	01-19-2006	Chen et al.	
	3.	US-5,212,071-A	05-18-1993	Fearon et al.	
	4.	US-5,328,470-A	07-12-1994	Nabel et al.	
	5.	US-5,472,939-A	12-05-1995	Fearon et al.	
	6.	US-5,851,528-A	12-22-1998	Ko et al.	
	7.	US-5,949,562-A	09-07-1999	Kubota et al.	
	8.	US-5,949,961-A	09-07-1999	Sharman	
	9.	US-5,981,481-A	11-09-1999	Fearon et al.	
	10.	US-6,140,472-A	10-31-2000	Rosengard et al.	
	11.	US-6,291,239-B1	09-18-2001	Prodinger et al.	
	12.	US-6,432,679-B1	08-13-2002	Mond et al.	
	13.	US-6,458,360-B1	10-01-2002	Fearon et al.	
	14.	US-6,503,947-B1	01-07-2003	Lipton et al.	
	15.	US-6,521,450-B1	02-18-2003	Atkinson et al.	
	16.	US-6,820,011-B2	11-16-2004	Chen et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	17.	EP-0 402 226-A1	12-12-1990	Institut National de la Recherche Agronomique		
	18.	WO-91/16437-A1	10-31-1991	The Johns Hopkins University		
	19.	WO-98/07835-A2, A3	02-26-1998	Sugen, Inc.		
	20.	WO-04/103288-A2, A3	12-02-2004	New York Society for the Ruptured and Crippled Maintaining the Hospital for Special Surgery et al.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	21.	Abrahmsen, L. et al. (April 30, 1991). "Engineering Subtilisin and Its Substrates for Efficient Ligation of Peptide Bonds in Aqueous Solution," *Biochemistry* 30(17):4151-4159.	
	22.	Ahearn, J.M. et al. (March 1996). "Disruption of the *Cr2* Locus Results in a Reduction in B-1a Cells and in an Impaired B Cell Response to T-Dependent Antigen," *Immunity* 4(3):251-262.	
	23.	Amsterdam, E.A. et al. (January 1995). "Limitation of Reperfusion Injury by a Monoclonal Antibody to C5a During Myocardial Infarction in Pigs," *Am. J. Physiol.* 268(1):H448-H457.	

Examiner Signature		Date Considered	

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/534,772
				Filing Date	(Int'l.) November 13, 2003
				First Named Inventor	Stephen TOMLINSON
				Art Unit	1653
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	2	of	8	Attorney Docket Number	577712000200

	24.	Andrews, B.S. et al. (October 1, 1978). "Spontaneous Murine Lupus-like Syndromes. Clinical and Immunopathological Manifestations in Several Strains," *J. Exp. Med.* 148(4):1198-1215.	
	25.	Aslam, M. et al. (June 22, 2001). "Folded-Back Solution Structure of Monomeric Factor H of Human Complement by Synchrotron X-ray and Neutron Scattering, Analytical Ultracentrifugation and Constrained Molecular Modelling," *J. Mol. Biol.* 309(5):1117-1138.	
	26.	Aubry, J-P. et al. (August 6, 1992). "CD21 is a Ligand for CD23 and Regulates IgE Production," *Nature* 358(6386):505-507.	
	27.	Bagshawe, K.D. et al. (1988). "A Cytotoxic Agent can be Generated Selectively at Cancer Sites," *Br. J. Cancer* 58:700-703.	
	28.	Bagshawe, K.D. (1989). "Towards Generating Cytotoxic Agents at Cancer Sites," *Br. J. Cancer* 60:275-281.	
	29.	Baranyi, L. et al. (August 1994). "Cell-Surface Bound Complement Regulatory Activity is Necessary for the *in vivo* Survival of KDH-8 Rat Hepatoma," *Immunology* 82(4):522-528.	
	30.	Barlow, P.N. et al. (July 5, 1993). "Solution Structure of a Pair of Complement Modules by Nuclear Magnetic Resonance," *J. Mol. Biol.* 232:268-284.	
	31.	Battelli, M.G. et al. (1992). "T Lymphocyte Killing by a Xanthine-Oxidase-Containing Immunotoxin," *Cancer Immunol. Immunother.* 35:421-425.	
	32.	Bergelson, J.M. et al. (June 21, 1994). "Decay-Accelerating Factor (CD55), A Glycosylphosphatidylinositol-Anchored Complement Regulatory Protein, Is a Receptor for Several Echoviruses," *Proc. Natl. Acad. Sci. USA* 91(13):6245-6249.	
	33.	Brown, V.I. et al. (July/August 1991). "Molecular and Cellular Mechanisms of Receptor-Mediated Endocytosis," *DNA and Cell Biology* 10(6):399-409.	
	34.	Cambier, J-C. (May 1997). "Signalling Processes in Haematopoietic Cells: Positive and Negative Signal Co-operativity in the Immune System: The BCR, FcγRIIB, CR2 Paradigm," *Biochem. Soc. Trans.* 25(2):441-445.	
	35.	Caragine, T.A. et al. (February 15, 2002). "A Tumor-Expressed Inhibitor of the Early but not Late Complement Lytic Pathway Enhances Tumor Growth in a Rat Model of Human Breast Cancer," *Cancer Res.* 62(4):1110-1115.	
	36.	Carel, J.C. et al. (July 25, 1990). "Structural Requirements for C3d,g/Epstein-Barr Virus Receptor (CR2/CD21) Ligand Binding, Internalization, and Viral Infection," *J. Biol. Chem.* 265(21):12293-12299.	
	37.	Carroll, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," *Annu. Rev. Immunol.* 16:545-568.	
	38.	Carroll, M.C. (2000). "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Dixon, F.J. ed., Academic Press, Inc., 74:61-88.	
	39.	Carter, R.H. et al. (April 3, 1992). "CD19: Lowering the Threshold for Antigen Receptor Stimulation of B Lymphocytes," *Science* 256:105-107.	
	40.	Casasnovas, J.M. et al. (1999). "Crystal Structure of Two CD46 Domains Reveals an Extended Measles Virus-Binding Surface," *EMBO J.* 18(11):2911-2922.	
	41.	Chen, S-H. et al. (April 12, 1994). "Gene Therapy for Brain Tumors: Regression of Experimental Gliomas by Adenovirus-Mediated Gene Transfer *in vivo*," *Proc. Natl. Acad. Sci. USA* 91(8):3054-3057.	
	42.	Chen, S. et al. (June 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma," *Cancer Res.* 60(11):3013-3018.	
	43.	Christiansen, D. et al. (March 1996). "A Functional Analysis of Recombinant Soluble CD46 *in vivo* and a Comparison with Recombinant Soluble Forms of CD55 and CD35 *in vitro*," *European Journal of Immunology* 26(3):578-585.	
	44.	Clemenza, L. et al. (October 1, 2000). "Structure-Guided Identification of C3d Residues Essential for Its Binding to Complement Receptor 2 (CD21)," *J. Immunol.* 165(7):3839-3848.	

Examiner Signature		Date Considered	

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/534,772
				Filing Date	(Int'l.) November 13, 2003
				First Named Inventor	Stephen TOMLINSON
				Art Unit	1653
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	3	of	8	Attorney Docket Number	577712000200

	45.	Davies, A. et al. (September 1, 1989). "CD59, an Ly-6-Like Protein Expressed in Human Lymphoid Cells, Regulates the Action of the Complement Membrane Attack Complex on Homologous Cells," *Journal of Experimental Medicine* 170(3):637-654.	
	46.	de Córdoba, S.R. et al. (2004). "The Human Complement Factor H: Functional Roles, Genetic Variations and Disease Associations," *Molecular Immunology* 41:355-367.	
	47.	Dempsey, P.W. et al. (January 19, 1996). "C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity," *Science* 271:348-350.	
	48.	Dev, S.B. et al. (January 1994). "Electrochemotherapy - A Novel Method of Cancer Treatment," *Cancer Treat. Rev.* 20(1):105-115.	
	49.	Diefenbach, R.J. et al. (March 1, 1995). "Mutation of Residues in the C3dg Region of Human Complement Component C3 Corresponding to a Proposed Binding Site for Complement Receptor Type 2 (CR2, CD21) Does Not Abolish Binding of iC3b or C3dg to CR2," *J. Immunol.* 154(5):2303-2320.	
	50.	Dierich, M.P. et al. (November 1988). "Structural and Functional Relationships Among Receptors and Regulators of the Complement System," *Mol. Immunol.* 25(11):1043-1051.	
	51.	Dörig, R.E. et al. (October 22, 1993). "The Human CD46 Molecule Is a Receptor for Measles Virus (Edmonston Strain)," *Cell* 75(2):295-305.	
	52.	Duits, A.J. et al. (1991). "Selective Enhancement of Leu-Cam Expression by Interleukin 6 During Differentiation of Human Promonocytic U937 Cells," *Scand. J. Immunol.* 33(2):151-159.	
	53.	Edwards, A.O. et al. (April 15, 2005). "Complement Factor H Polymorphism and Age-Related Macular Degeneration," *Science* 308(5720):421-424.	
	54.	Fearon, D.T. (October 1998). "The Complement System and Adaptive Immunity," *Semin. Immunol.* 10(5):355-361.	
	55.	Fearon, D.T. et al. (1995). "The CD19/CR2/TAPA-1 Complex of B Lymphocytes: Linking Natural to Acquired Immunity," *Annu. Rev. Immunol.* 13:127-149.	
	56.	Fingeroth, J.D. et al. (July 1984). "Epstein-Barr Virus Receptor of Human B Lymphocytes is the C3d Receptor CR2," *Proc. Natl. Acad. Sci. USA* 81(14):4510-4514.	
	57.	Fingeroth, J.D. et al. (January 1989). "Identification of Murine Complement Receptor Type 2," *Proc. Natl. Acad. Sci. USA* 86(1):242-246.	
	58.	Frémeaux-Bacchi, V. et al. (December 1998). "Soluble CD21 Induces Activation and Differentiation of Human Monocytes Through Binding to Membrane CD23," *Eur. J. Immunol.* 28:4268-4274.	
	59.	Girardi, G. et al. (December 2003). "Complement C5a Receptors and Neutrophils Mediate Fetal Injury in the Antiphospholipid Syndrome," *J. Clin. Invest.* 112(11):1644-1654.	
	60.	Goodford, P.J. (July 1985). "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules," *J. Med. Chem.* 28(7):849-857.	
	61.	Gordon, J. (September 1994). "B-cell Signaling *via* the C-type Lectins CD23 and CD72," *Immunol. Today* 15(9):411-417.	
	62.	Guthridge, J.M. et al. (November 15, 2001). "Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface," *J. Immunol.* 167:5758-5766.	
	63.	Guthridge, J.M. et al. (May 22, 2001). "Structural Studies in Solution of the Recombinant N-Terminal Pair of Short Consensus/Complement Repeat Domains of Complement Receptor Type 2 (CR2/CD21) and Interactions with its Ligand C3dg," *Biochemistry* 40:5931-5941.	
	64.	Hageman, G.S. et al. (May 17, 2005). "A Common Haplotype in the Complement Regulatory Gene Factor H (*HF1/CFH*) Predisposes Individuals to Age-Related Macular Degeneration," *Proc. Natl. Acad. Sci. USA* 102(20):7227-7232.	

Examiner Signature		Date Considered	

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)* Sheet 4 of 8	*Complete if Known*	
	Application Number	10/534,772
	Filing Date	(Int'l.) November 13, 2003
	First Named Inventor	Stephen TOMLINSON
	Art Unit	1653
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	577712000200

	65.	Haines, J.L. et al. (April 15, 2005). "Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration," *Science* 308:419-421.	
	66.	Harris, C.L. et al. (November 2002). "Tailoring Anti-Complement Therapeutics," *Biochemical Society Transactions* 30(6):1019-1026.	
	67.	Hebell, T. et al. (October 4, 1991). "Suppression of the Immune Response by a Soluble Complement Receptor of B Lymphocytes," *Science* 254:102-105.	
	68.	Heyman, B. (2000). "Regulation of Antibody Responses via Antibodies, Complement, and Fc Receptors," *Ann. Rev. Immunol.* 18:709-737.	
	69.	Higgins, P.J. et al. (March 15, 1997). "A Soluble Chimeric Complement Inhibitory Protein That Possesses Both Decay-Accelerating and Factor I Cofactor Activities," *J. Immunol.* 158(6):2872-2881.	
	70.	Holers, V.M. (1989). "Complement Receptors" *In* The Year In Immunology 1988. Cellular, Molecular and Clinical Aspects, Cruse, J.M. et al. eds., Basel, Karger, 4:231-240.	
	71.	Homeister, J.W. et al. (February 1, 1993). "Soluble Complement Receptor Type 1 Prevents Human Complement-Mediated Damage of the Rabbit Isolated Heart," *J. Immunol.* 150(3):1055-1064.	
	72.	Hori, Y. et al. (December 1999). "Crry, a Complement Regulatory Protein, Modulates Renal Interstitial Disease Induced by Proteinuria," *Kidney Int.* 56(6):2096-2106.	
	73.	Hsu, S.I-H. et al. (2003). "Chronic Progression of Tubulointerstitial Damage in Proteinuric Renal Disease Is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors?" *J. Am. Soc. Nephrol.* 14:S186-S191.	
	74.	Hughes, B.J. et al. (November 15, 1989). "Monoclonal Antibody Targeting of Liposomes to Mouse Lung *in Vivo*," *Cancer Research* 49(22):6214-6220.	
	75.	Humblet, C. et al. (1993). "3D Database Searching and Docking Strategies" Chapter 29 *In* "Topics in Drug Design and Discovery" Section VI *In* Animal Reports in Medicinal Chemistry, Bristol, J.A. et al. eds., Academic Press, Inc.: San Diego, CA, 28:275-283.	
	76.	International Search Report mailed September 15, 2004, for PCT Application No. PCT/US03/36459 filed November 13, 2003, three pages.	
	77.	Józsi, M. et al. (2004). "Attachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology," *Histol. Histopathol.* 19:251-258.	
	78.	Kalli, K.R. et al. (July 15, 1991). "Interaction of iC3b With Recombinant Isotypic and Chimeric Forms of CR2," *J. Immunol.* 147(2):590-594.	
	79.	Kaplan, M. (2002). "Eculizumab Alexion," *Curr. Opin. Investig. Drugs* 3(7):1017-1023.	
	80.	Khurana, S. et al. (June 9, 1998). "Crystal Structure of 2,5-diketo-D-gluconic Acid Reductase A Complexed with NADPH at 2.1-Å Resolution," *Proc. Natl. Acad. Sci.* 95(12):6768-6773.	
	81.	Klein, R.J. et al. (April 15, 2005). "Complement Factor H Polymorphism in Age-Related Macular Degeneration," *Science* 308(5720):385-389.	
	82.	Koski, C.L. et al. (June 1983). "Cytolysis of Nucleated Cells by Complement: Cell Death Displays Multi-hit Characteristics," *Proc. Natl. Acad. Sci. USA* 80(12):3816-3820.	
	83.	Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Xenotransplantation," *Transplantation* 60(11):1194-1202.	
	84.	Kroshus, T.J. et al. (June 15, 2000). "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD55 Reduces Acute Cardiac Tissue Injury in Models of Pig-to-Human Heart Transplantation," *Transplantation* 69(11):2282-2289.	
	85.	Lambris, J.D. et al. (June 1985). "Mapping of the C3d Receptor (CR2)-Binding Site and a Neoantigenic Site in the C3d Domain of the Third Component of Complement," *Proc. Natl. Acad. Sci. USA* 82(12):4235-4239.	
	86.	Law, S.K. et al. (March 1979). "Action of the C3b-Inactivator on Cell-Bound C3b," *J. Immunol.* 122(3):759-765.	

Examiner Signature		Date Considered	

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/534,772
				Filing Date	(Int'l.) November 13, 2003
				First Named Inventor	Stephen TOMLINSON
				Art Unit	1653
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	5	of	8	Attorney Docket Number	577712000200

	87.	Law, S.K.A. et al. (1995). "Complement" *In* In Focus, Second Edition, Male, D. ed., IRL Press at Oxford University Press, Inc.: New York, NY, pp. vii - ix (Table of Contents Only.)	
	88.	Linton, S.M. et al. (November 2000). "Therapeutic Efficacy of a Novel Membrane-Targeted Complement Regulator in Antigen-Induced Arthritis in the Rat," *Arthritis Rheum.* 43(11):2590-2597.	
	89.	Litzinger, D.C. et al. (1992). "Biodistribution and Immunotargetability of Ganglioside-Stabilized Dioleoylphosphatidylethanolamine Liposomes," *Biochimica et Biophysica Acta.* 1104:179-187.	
	90.	Lowell, C.A. et al. (December 1, 1989). "Mapping of the Epstein-Barr Virus and C3dg Binding Sites to a Common Domain on Complement Receptor Type 2," *J. Exp. Med.* 170(6):1931-1946.	
	91.	Martin, D.R. et al. (December 1991). "Determination of the Structural Basis for Selective Binding of Epstein-Barr Virus to Human Complement Receptor Type 2," *J. Exp. Med.* 174:1299-1311.	
	92.	Martin, D.R. et al. (August 1994). "Determination of the Role for CD21 During Epstein-Barr Virus Infection of B-Lymphoblastoid Cells," *J. Virol.* 68(8):4716-4726.	
	93.	Matsumoto, A.K. et al. (January 1,1991). "Intersection of the Complement and Immune Systems: A Signal Transduction Complex of the B Lymphocyte-Containing Complement Receptor Type 2 and CD19," *J. Exp. Med.* 173(1):55-64.	
	94.	Mendrick, D.L. et al. (1983). "Monoclonal Antibodies Against Rat Glomerular Antigens: Production and Specificity," *Laboratory Investigation* 49(1):107-117.	
	95.	Mendrick, D.L. et al. (1988). "I. Induction of Proteinuria in the Rat by a Monoclonal Antibody Against SGP-115/107," *Kidney Int.* 33:818-830.	
	96.	Meri, S. et al. (June 15, 1996). "Structural Composition and Functional Characterization of Soluble CD59: Heterogeneity of the Oligosaccharide and Glycophosphoinositol (GPI) Anchor Revealed by Laser-Desorption Mass Spectrometric Analysis," *Biochem J.* 316(Pt.3):923-935.	
	97.	Moir, S. et al. (September 4, 2000). "B Cells of HIV-1-Infected Patients Bind Virions Through CD21-Complement Interactions and Transmit Infectious Virus to Activated T Cells," *J. Exp. Med.* 192(5):637-645.	
	98.	Molina, H. et al. (July 5, 1991). "Analysis of Epstein-Barr Virus-Binding Sites on Complement Receptor 2 (CR2/CD21) Using Human-Mouse Chimeras and Peptides," *J. Biol. Chem.* 266(19):12173-12179.	
	99.	Molina, H. et al. (July 15, 1994). "Analysis of C3b/C3d Binding Sites and Factor I Cofactor Regions Within Mouse Complement Receptor 1 and 2," *J. Immunol.* 153(2):789-795.	
	100.	Molina, H. et al. (May 15, 1995). "Characterization of a Complement Receptor 2 (CR2, CD21) Ligand Binding Site for C3," *J. Immunol.* 154(10):5426-5435.	
	101.	Molina, H. et al. (April 1996). "Markedly Impaired Humoral Immune Response in Mice Deficient in Complement Receptors 1 and 2," *Proc. Natl. Acad. Sci. USA* 93:3357-3361.	
	102.	Moran, P. et al. (September 1, 1992). "Human Recombinant Soluble Decay Accelerating Factor Inhibits Complement Activation *in vitro* and *in vivo*," *J. Immunol.* 149(5):1736-1743.	
	103.	Morgan, B.P. (April 1994). "Clinical Complementology: Recent Progress and Future Trends," *Eur. J. Clin. Invest.* 24(4):219-228.	
	104.	Müller-Eberhard, H.J. (1988). "Molecular Organization and Function of the Complement System," *Ann. Rev. Biochem.* 57:321-347.	
	105.	Mulligan, M.S. et al. (April 15, 1999). "Endothelial Targeting and Enhanced Antiinflammatory Effects of Complement Inhibitors Possessing Sialyl Lewis^{X} Moieties," *J. Immunol.* 162(8):4952-4959.	
	106.	Nagar, B. et al. (May 22, 1998). "X-Ray Crystal Structure of C3d: A C3 Fragment and Ligand for Complement Receptor 2," *Science* 280:1277-1281.	
	107.	Okano, M. (January 1998). "Epstein-Barr Virus Infection and its Role in the Expanding Spectrum of Human Diseases," *Acta Paediatr.* 87:11-18.	

Examiner Signature		Date Considered	

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)* Sheet 6 of 8	*Complete if Known*	
	Application Number	10/534,772
	Filing Date	(Int'l.) November 13, 2003
	First Named Inventor	Stephen TOMLINSON
	Art Unit	1653
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	577712000200

	108.	Pietersz, G.A. et al. (1992). "Antibody Conjugates for the Treatment of Cancer," *Immunolog. Reviews* 129:57-80.	
	109.	Poznansky, M.C. et al. (August 15, 1989). "The Difference Between Human C3F and C3S Results From a Single Amino Acid Change From an Asparagine to an Aspartate Residue at Position 1216 on the α-Chain of the Complement Component, C3," *J. Immunol.* 143(4):1254-1258.	
	110.	Prodeus, A.P. et al. (November 1998). "A Critical Role for Complement in Maintenance of Self-Tolerance," *Immunity* 9(5):721-731.	
	111.	Prodinger, W.M. et al. (November 1, 1998). "Characterization of C3dg Binding to a Recess Formed Between Short Consensus Repeats 1 and 2 of Complement Receptor Type 2 (CR2; CD21)," *J. Immunol.* 161(9):4604-4610.	
	112.	Quigg, R.J. et al. (May 1, 1998). "Blockade of Antibody-Induced Glomerulonephritis with Crry-Ig, a Soluble Murine Complement Inhibitor," *J. Immunol.* 160(9):4553-4560.	
	113.	Quigg, R.J. et al. (January 2000). "Production and Functional Analysis of Rat CD59 and Chimeric CD59-Crry as Active Soluble Proteins in *Pichia pastoris*," *Immunology* 99(1):46-53.	
	114.	Rabinovici, R. et al. (September 1, 1992). "Role of Complement in Endotoxin/Platelet-Activating Factor-Induced Lung Injury," *J. Immunol.* 149(5):1744-1750.	
	115.	Ramm, L.E. et al. (August 1982). "Transmembrane Channel Formation by Complement: Functional Analysis of the Number of C5b6, C7, C8, and C9 Molecules Required for a Single Channel," *Proc. Natl. Acad. Sci. USA* 79(15):4751-4755.	
	116.	Rao, P.E. et al. (July 1985). "OKB7, A Monoclonal Antibody That Reacts at or Near the C3d Binding Site of Human CR2," *Cell. Immunol.* 93(2):549-555.	
	117.	Rinder, C.S. et al. (September 1995). "Blockade of C5a and C5b-9 Generation Inhibits Leukocyte and Platelet Activation During Extracorporeal Circulation," *J. Clin. Invest.* 96(3):1564-1572.	
	118.	Rioux, P. (2001). "TP-10 AVANT Immunotherapeutics," *Curr. Opin. Investig. Drugs* 2:364-371.	
	119.	Ritterhaus, C.W. et al. (April 16, 1999). "Recombinant Glycoproteins That Inhibit Complement Activation and Also Bind the Selectin Adhesion Molecules," *J. Biol. Chem.* 274(16):11267-11244.	
	120.	Roffler, S.R. et al. (October 24, 1991). "Anti-Neoplastic Glucuronide Prodrug Treatment of Human Tumor Cells Targeted with a Monoclonal Antibody-Enzyme Conjugate," *Biochem. Pharmacol.* 42(10):2062-2065.	
	121.	Ross, G.D. et al. (February 1992). "Macrophage Cytoskeleton Association with CR3 and CR4 Regulates Receptor Mobility and Phagocytosis of iC3b-opsonized Erythrocytes," *J. Leukoc. Biol.* 51(2):109-117.	
	122.	Rothlein, R. et al. (May 1, 1986). "The Requirement for Lymphocyte Function-Associated Antigen 1 in Homotypic Leukocyte Adhesion Stimulated by Phorbol Ester," *J. Exp. Med.* 163(5):1132-1149.	
	123.	Rushmere, N.K. et al. (February 2000). "Production and Functional Characterization of a Soluble Recombinant Form of Mouse CD59," *Immunology* 99(2):326-332.	
	124.	Salerno, C.T. et al. (March 2002). "A Soluble Chimeric Inhibitor of C3 and C5 Convertases, Complement Activation Blocker-2, Prolongs Graft Survival in Pig-to-Rhesus Monkey Heart Transplantation," *Xenotransplantation* 9(2):125-134.	
	125.	Schwarzenbacher, R. et al. (November 15, 1999). "Crystal Structure of Human β2-glycoprotein I: Implications for Phospholipid Binding and the Antiphospholipid Syndrome," *EMBO J.* 18(22):6228-6239.	
	126.	Senter, P.D. et al. (November/December 1991). "Generation of 5-Fluorouracil From 5-Fluorocytosine by Monoclonal Antibody-Cytosine Deaminase Conjugates," *Bioconjugate Chem.* 2(6):447-451.	

Examiner Signature		Date Considered	

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/534,772
				Filing Date	(Int'l.) November 13, 2003
				First Named Inventor	Stephen TOMLINSON
				Art Unit	1653
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	7	of	8	Attorney Docket Number	577712000200

	127.	Senter, P.D. et al. (January/February 1993). "Generation of Cytotoxic Agents by Targeted Enzymes," *Bioconjugate Chem.* 4(1):3-9.	
	128.	Seya, T. et al. (1985). "Limited Proteolysis of Complement Protein C3b by Regulatory Enzyme C3b Inactivator: Isolation and Characterization of a Biologically Active Fragment, C3d,g," *J. Biochem.* 97(1):373-382.	
	129.	Sharkey, R.M. et al. (April 15, 1990). "Biodistribution and Radiation Dose Estimates for Yttrium- and Iodine-Labeled Monoclonal Antibody IgG and Fragments in Nude Mice Bearing Human Colonic Tumor Xenografts," *Cancer Res.* 50:2330-2336.	
	130.	Sharkey, R.M. et al. (June 15, 1991). "Rapid Blood Clearance of Immunoglobulin G2a and Immunoglobulin G2b in Nude Mice," *Cancer Res.* 51:3102-3107.	
	131.	Sheerin, N.S. et al. (October 2002). "Leaked Protein and Interstitial Damage in the Kidney: Is Complement the Missing Link?" *Clin. Exp. Immunol.* 130(1):1-3.	
	132.	Smith, G.P. et al. (2001). "Membrane-Targeted Complement Inhibitors," *Mol. Immunol.* 38:249-255.	
	133.	Song, H. et al. (June 2003). "Complement Receptor 2-Mediated Targeting of Complement Inhibitors to Sites of Complement Activation," *J. Clin. Invest.* 111(12):1875-1885.	
	134.	Sugita, Y. et al. (May 1994). "Recombinant Soluble CD59 Inhibits Reactive Haemolysis with Complement," *Immunology* 82(1):34-41.	
	135.	Supplementary Partial European Search Report mailed April 3, 2006, for EP Application No. 03796403.8 filed November 13, 2003, three pages.	
	136.	Supplementary European Search Report mailed July 3, 2006, for EP Application No. 03796403.8 filed November 13, 2003, four pages.	
	137.	Szakonyi, G. et al. (June 1, 2001). "Structure of Complement Receptor 2 in Complex with Its C3d Ligand," *Science* 292(5522):1725-1728.	
	138.	Takeda, J. et al. (1986). "Number of Hits Necessary for Complement-Mediated Hemolysis," *Microbiol. Immunol.* 30(5):461-468.	
	139.	Ten, R.M. et al. (October 1, 1999). "The Signal Transduction Pathway of CD23 (FcεRIIb) Targets IκB Kinase," *J. Immunol.* 163(7):3851-3857.	
	140.	Tsutsumi, Y. et al. (July 18, 2000). "Site-Specific Chemical Modification with Polyethylene Glycol of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) Improves Antitumor Activity and Reduces Animal Toxicity and Immunogenicity," *Proc. Natl. Acad. Sci. USA* 97(15):8548-8553.	
	141.	Wang, Y. et al. (September 12, 1995). "Anti-C5 Monoclonal Antibody Therapy Prevents Collagen-Induced Arthritis and Ameliorates Established Disease," *Proc. Natl. Acad. Sci. USA* 92(19):8955-8959.	
	142.	Wang, Y. et al. (August 6, 1996). "Amelioration of Lupus-Like Autoimmune Disease in NZB/W F_1 Mice After Treatment with a Blocking Monoclonal Antibody Specific for Complement Component C5," *Proc. Natl. Acad. Sci. USA* 93(16):8563-8568.	
	143.	Ward, T. et al. (November 1, 1994). "Decay-Accelerating Factor CD55 is Identified as the Receptor for Echovirus 7 Using CELICS, a Rapid Immuno-Focal Cloning Method," *EMBO J.* 13(21):5070-5074.	
	144.	Weisman, H.F. et al. (July 13, 1990). "Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis," *Science* 249(4965):146-151.	
	145.	Whiss, P.A. (2002). "Pexelizumab Alexion," *Curr. Opin. Investig. Drugs* 3(6):870-877.	
	146.	Wiles, A.P. et al. (1997). "NMR Studies of a Viral Protein that Mimics the Regulators of Complement Activation," *J. Mol. Biol.* 272(2):253-265.	
	147.	Yu, J. et al. (January 1999). "Protection of Human Breast Cancer Cells from Complement-Mediated Lysis by Expression of Heterologous CD59," *Clin. Exp. Immunol.* 115(1):13-18.	

Examiner Signature		Date Considered	

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/534,772
				Filing Date	(Int'l.) November 13, 2003
				First Named Inventor	Stephen TOMLINSON
				Art Unit	1653
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	8	of	8	Attorney Docket Number	577712000200

	148.	Zhang, H-F. et al. (January 1999). "Targeting of Functional Antibody-CD59 Fusion Proteins to a Cell Surface," *J. Clin. Invest.* 103(1):55-66.	
	149.	Zhang, H-F. et al. (July 20, 2001). "Targeting of Functional Antibody-Decay-Accelerating Factor Fusion Proteins to a Cell Surface," *J. Biol. Chem.* 276(29):27290-27295.	
	150.	Zipfel, P.F. (June 2001). "Complement Factor H: Physiology and Pathophysiology," *Seminars in Thrombosis Hemostasis* 27(3):191-199.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	